Corneal Endothelial Cell Differentiation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating corneal endothelial cell-like cells from pluripotent stem cells are complex and not suitable for large-scale, reproducible production, lacking a fast and simple protocol.
Innovation Solution
A method involving culturing pluripotent stem cells with a TGF-beta inhibitor, a Wnt activator, and retinoic acid, followed by continued culture with the TGF-beta inhibitor and Wnt activator but decreasing or removing retinoic acid, using specific agents like SB431542 and CHIR99021, to produce corneal endothelial cell-like cells efficiently.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing differentiation protocols are used to produce CEC-like cells from pluripotent stem cells, then CEC-like cells can be obtained, but the process is complex and not suitable for large-scale, reproducible production
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the concentrations and combinations of small molecule inhibitors (such as CHIR99021 for Wnt pathway, SB431542 for TGF-beta pathway) and growth factors (such as bFGF, EGF, ATRA) in the differentiation medium. By adjusting these chemical parameters, the protocol achieves rapid and reproducible CEC-like cell production from hPSCs within 7-14 days, simplifying the complex differentiation process while maintaining high productivity.
2Speed
If existing differentiation protocols are used, then CEC-like cells can be differentiated, but the protocol is not fast and simple
Solution Approach 1:
The differentiation protocol is segmented into distinct temporal phases with specific medium compositions: initial differentiation phase (days 0-3) using inhibitors and growth factors, intermediate phase (days 3-7) with adjusted factors, and maturation phase (days 7-14) for CEC-like cell development. This segmentation enables rapid differentiation while simplifying operational steps at each stage, achieving both speed and ease of operation.
Solution Approach 2:
The protocol employs preliminary action by pre-defining the optimal sequence and timing of adding/removing specific factors (inhibitors, growth factors, retinoids) before differentiation begins. The staged approach with predetermined medium changes ensures rapid and reproducible CEC-like cell generation, making the protocol both fast and simple to execute.
3Quantity of substance
If large-scale production of CEC-like cells is pursued, then more cells can be produced, but reproducibility and quality control become challenging
Solution Approach 1:
The patent establishes defined parameter ranges for all differentiation factors (concentrations of CHIR99021: 3-10 µM, SB431542: 5-20 µM, bFGF: 10-50 ng/mL, EGF: 10-50 ng/mL, ATRA: 1-10 µM) and culture conditions (temperature: 37°C, CO2: 5%, humidity: 95%). These standardized parameters enable reproducible large-scale production of CEC-like cells with consistent quality and characteristics across different batches and scales.
Data Source
AI summary
The present invention relates to differentiation of corneal endothelial cell (CEC)-like cells from pluripotent stem cells. The invention also relates to CEC-like cells obtainable by the differentiation method, to uses thereof and to preparations comprising the same.